← 產業報告目錄
Allogeneic Cell Therapy Manufacturing Market Size, Share & Trends Analysis Report By Product, By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations), By Region, And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-31頁數 170報告編號 INSIGHTACE-0ecd5c288b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Industry analysis indicates the Allogeneic Cell Therapy Manufacturing Market globally will develop at a 15.0% CAGR during 2025–2034.
Allogeneic Cell Therapy Manufacturing encompasses key industry insights & findings from the report:
The rise in chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases represents a major driver. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and expanding investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Allogeneic Cell Therapy Manufacturing Market Snapshot
Chapter 4. Global Allogeneic Cell Therapy Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Allogeneic Cell Therapy Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. By Products, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
5.2.1. Induced pluripotent stem cells (iPSC)
5.2.2. T-cells and Natural killer (NK) cells
5.2.3. Human pluripotent stem cells (hPSCs)
5.2.4. Mesenchymal stem cells (MSC)
5.2.5. β-cells
5.2.6. Neurons
5.2.7. Immortalized and engineered cell lines
5.2.8. Tissue engineered product
Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis
6.1. By Scale of Operation & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operation
6.2.1. Preclinical Scale Operations
6.2.2. Clinical Scale Operations
6.2.3. Commercial Scale Operations
Chapter 7. Allogeneic Cell Therapy Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034
7.1.2. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2021-2034
7.1.3. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.2. Europe
7.2.1. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.2.2. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.2.3. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2021-2034
7.3.2. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2021-2034
7.3.3. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.4.2. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.4.3. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2021-2034
7.5.2. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2021-2034
7.5.3. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Lonza Group
8.2.2. KBI Biopharma, Inc.
8.2.3. Waisman Biomanufacturing
8.2.4. Cell and Gene Therapy Catapult
8.2.5. Thermo Fisher Scientific, Inc.
8.2.6. Merck KGaA
8.2.7. Catalent Inc.
8.2.8. Lonza Group
8.2.9. Oxford Biomedica Plc
8.2.10. Fujifilm Cellular Dynamics, Inc.
8.2.11. Wuxi Apptec
8.2.12. Charles River Laboratories International, Inc.
8.2.13. The Discovery Labs LLC
8.2.14. ABL, Inc.
8.2.15. BioCentriq
8.2.16. Commercializing Living Therapies
8.2.17. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們